Go back

Chemotherapy Induced Peripheral Neuropathy (CIPN): Neuroimmune Crosstalk and Inflammation in Chemotherapy-induced Peripheral Neuropathy

25m 58s

Chemotherapy Induced Peripheral Neuropathy (CIPN): Neuroimmune Crosstalk and Inflammation in Chemotherapy-induced Peripheral Neuropathy

Chemotherapy-induced peripheral neuropathy (CIPN) is increasingly understood as a neuroimmune disorder rather than purely a direct neurotoxic effect. Preclinical studies highlight the role of innate immune activation—particularly through macrophages and cytokines—driven by sensory neuron injury and resulting in bidirectional neuroimmune crosstalk. However, translating these findings to patients remains challenging due to variability in cancer types, treatment regimens, and baseline immune status. The skin, once viewed merely as a site of nerve fiber loss, is now recognized as a dynamic neurocutaneous environment where cancer cells, immune cells, and epithelial stress contribute to inflammation and sensory dysfunction. While circulating biomarkers show potential, their clinical relevance is limited; instead, patient-specific phenotyping linked to localized tissue biology (e.g., skin biopsies) offers a more meaningful pathway for diagnosis and monitoring. Research is shifting toward integrated models that combine preclinical data with longitudinal clinical observations to identify distinct CIPN subtypes. Key advances will come from understanding how immune responses evolve over time—from acute injury to chronic symptoms—and developing targeted, stage-specific therapies that do not compromise cancer treatment efficacy. Ultimately, the field aims toward mechanism-informed, personalized approaches to CIPN care, enabling early prediction, prevention, and effective intervention based on individual patient biology.

Transcription

3688 Words, 23533 Characters

English
[Music] Welcome to the peripheral nerve podcast, the official podcast of the peripheral nerve society, exploring topics in peripheral nerve disorders, awareness, education, and advocacy. We are your host, Professor Sizana Park from the University of Sydney, Australia, and Dr. Paola Batting from University of Milano Bicocca, Italy. We are delighted to bring you another episode in the peripheral nerve podcast series understanding chemotherapy induced peripheral neuropathy. In this episode we're so excited to welcome Assistant Professor Grace Shin from Ohio State University Department of Neurology. Dr. Shin is a founding scientist at the Ohio State University CIPN clinic, as well as the member of the Comprehensive Cancer Center at the Neuroscience Research Institute, the Institute of Brain Behavior and Immunology, as well as the Department of Dermatology. She previously undertook postdoctoral work focused on CIPN Translational Neuroscience at Columbia University. Dr. Shin's group's work focuses on peripheral mechanisms of sensory neuro injury, inflammation, and resilience in skin, using multiple methods across proclinical and clinical settings. Today, we will discuss the topic of Neuromon Costolt and Information in chemotherapy induced peripheral neuropathy. We are honored to have you here, speak with us today. Yeah, thank you so much for inviting me. It's really an honor to be part of this series and to have this opportunity to talk about neuroimmune mechanisms in CIPN. To kick start our conversation, I would like to ask you what do we currently understand about the Neuromon mechanism that drives CIPN, including any specific roles for the microglia and microphages. This is an excellent question, because neuroinflammation is now considered one of the major mechanisms contributing to CIPN. But I would like to start with an important caveat to this. Much of what we know is still comes from preclinical models. Mouse and red studies have taught us great deal, but we still have a more limited understanding of which neuroimmune mechanisms are most active in patients. So, if we can start from the preclinical work, one of the best developed themes is activation of innate immune signaling in and around the peripheral sensory nervous system. Many studies have implicated TLR-4 related pathways, macrophages, satellite glia cells and cytokines such as TNF-RFA, IL-6, and IL-1-Bira in multiple chemotherapy models. They're also emerging studies on adaptive immune cells and systemic mortifiers such as microbiome, but the most consistent evidence so far is still around innate immune responses. So, one way to think about this is as biodeirectional neuroimmune crosstalk and amplification between injure sensory neurons and non-neuronal cells. Chemotherapy may first stress or injure sensory neurons and surrounding support cells, and that injury can release dangerous signals such as ATP and other damage associated signals, which then activate nearby glial cells and immune cells. And these activated macrophages and satellite glial cells can release cytokines and chemokines that recruit additional immune cells and further sensitize sensory neurons. So, the immune response doesn't really simply sit downstream of nerve injury, but once they're activated, it can run in peril with neuronal injury and amplify and sustain nerve dysfunction. So, from the immune cell side, macrophages are one of the most important and best studied periphery immune cell types in CIPN. They have been studied in the doors of root ganglia, preferred nerve, and in a small number of studies, preferred tissues such as skin. One thing that becomes very clear when you look at tissue closely is that macrophages are a collection of cells with many different states and subcategories. This is something we think about a lot in my lab. If you look at macrophages by subtype, activation state, and even by where they're located relative to sensory axons, blood, assholes, or the vitamins, they can look and behave very differently. And I think that this immediately changes the question. It's not really simply our macrophage numbers increased, but whether which macrophage state and which tissue compartment and at what time point is most relevant to CIPN. And that timing issue is something that I would really emphasize, because macrophages are dynamic and heterogeneous. Their role may be very different during early injury phase compared with the chronic phase or repair phase. With the second cell type, microglia also appeared to be important, and a small number of studies have shown that particularly when we're thinking about spinal cord mechanisms and sensory sensitization. Studies suggest that the microactivation contributes to early pain signaling and long-term changes in the central nervous system. But with all these cell types, the relative contribution of macrophages that are likely to cells in microglia likely depends on chemotherapy agent and timing, sex, model system, and whether we are studying acute pain, persistent pain or excellent regeneration that may or may not be coupled with pain. So all together, I'll summarize in this way. We now know that CIPN is not only a direct neurotoxicity problem, and chemotherapy can activate innate immune pathways in and around sensory nervous system, often through injury signals first generated by neurons, and there's a rounding micro apartment. So the next step is to really understand which of these neuroimmune interactions that we study in pre-clinical models actually do occur in patients and in which tissues and which stage of CIPN. And in my opinion, most importantly, which of these neuroimmune changes are most relevant to symptom severity and chronicity in the clinic. Thank you so much, Grace. Following up on that, if I could ask, what do we currently know about changes in the skin environment, which might drive near inflammation during neurotoxic chemotherapy treatment? Yeah, this is still an emerging and relatively under developed area in CIPN, but this is actually one of the areas I find most exciting. Historically, skin has often been treated mainly as the place where we measure intraepiderminerve fiber loss, which is the loss of sensory nerve endings embedded in the epidermis. But as you can imagine, skin is not a passive organ. Sensory nerve endings sit in close contact with carcinocytes, fibroblast, vascular cells, and immune cells. So together, these cells form an active neurocutaneous environment. And this is exactly why skin is so interesting to us. In our work, we think about skin not only as a place to count nerve fibers, but as a neuronal environment, microenvironment, where nerves, immune cells, and epicelial cells and best culture are all interacting with one another. So when you look at it this way, the question becomes more nuanced. It's not really only our nerve fibers lost, but it's also what kind of local tissue environment are those nerve fibers losing contact with or whether they could still interact with. So we don't really have enough studies showing exactly how chemotherapy models disembaram in patients. But we can actually learn a great deal from inflammatory skin disease, pain biology, and basic studies of neuro skin communication. So from those fields, I think there are several plausible ways that the skin environment could contribute to your inflammation during the IPN. So first scenario that I can think of is that the carcinocytes themselves may respond to chemotherapy and alter sensory neuron function. This is the best area that has been worked out, work from Stucky, Catarina, Visory, and Talogus, and other groups has really changed how we think about carcinocytes. These cells can participate in treating sensory signaling through mechanisms such as ATP signaling, on trip channel mediated sensory pathways, and direct carcinocytes sensory neuron communication. And most recent workers extended this idea in the CIPN field as well, where Pagletoxal induced mechanical hairpersensitivity through PH1 was mediating changes in carcinocytes and contributing to the CIPN pathology. And that was an important conceptual shift because it suggested that carcinocytes are not just passive neighbors of sensory pendings but they may actively participate in sensory signaling after chemotherapy. The second case that we can think about is nerve degeneration, nerve degeneration itself may actually be modeled as skin environment. So if sensory fibers retract from the epidermis, the loss of normal neuron to skin communication may trigger stress repair or innate immune programs in the tissue. So inflammation may not only be the upstream of nerve injury but also be a consequence of denurbation that feeds back onto the remaining sensory nerve fibers. And finally, there may be direct immune modeling in the skin. From other inflammatory skin and pain conditions, we we know that cardinal size and fiberglass can produce cytokines and chemokines, and that mast cells, macrophages, neutrophils, and other immune cells can shape local centering nerve function. In SAPIEN, this is still much less developed, but there is some evidence from human skin biopsy studies suggesting local immune changes. So altogether, the broad concept is that SAPIEN may involve pathological neurocutaneous niche. It is not just injure neurons in isolation, but injure neurons interacting with remodel skin environment, one that may include epithelial stress, fiberglass activation, vascular changes and immune cell recruitment, and alter communication between skin cells and sensory nerve terminals. I think this really matters because skin is clinically accessible and biologically active organ, and it is directly connected to the sensory symptoms patients experience. So by studying the skin environment more carefully, we may be able to understand not only where nerve fibers are lost, but also how local neuro-neeming interactions contribute to ongoing inflammation, pain, numbness, and sensory dysfunction in SAPIEN. Thank you so much for this clear card overview. It's coming out from this. Do you see that neuromont pathways offer potential biomarkers or therapeutic approaches for SAPIEN? Yes, I definitely think neuromont pathways offer potential biomarkers and therapeutic approaches for SAPIEN, but at this stage, I would be cautious about oversimplifying this. I don't think we're really at the point where one circulating cytokine can diagnose SAPIEN or one inflammatory target will work for everyone. So in preclinical models, inflammatory pathways are quite convincing. We see changes in macrophages, glial cells, and cytokines, and these pathways can sensitize neurons that may contribute to pain and longer term nerve dysfunction. But when you look at the studies from patient cohort, plus by cytokine data are more mixed than what we see in preclinical studies. And to be honest, I don't think that is really surprising. Cancer patients are highly heterogeneous. They are different in age, cancer type, chemotherapy exposure, and they have comorbidities. They may have baseline inflammation, medications, and they may be also measured in a different timing relative to treatment. So with this in mind, I think the field needs to move toward a more patient informed biomarker approach. Instead of asking only whether one inflammatory marker is higher, we can ask whether certain patients have a neuroinnovine or inflammatory state that maps onto symptoms, nerve injuries, king pathology, or treatment response. And I also think that the tissue biomarker can be very important. Plasma is very useful because it is accessible and especially in the cancer treatment setting. But it may not fully capture what is happening locally in Dorsal Look Anglia, Perfer Nerve or Skin, which are the migraine environments of the neurons. So of course, Dorsal Look Anglia and Perfer Nerves are not rarely accessible in most CIPM patients. But skin biopsy is much more feasible. And as we discussed, it may help connecting the circulating biomarkers with local neurocutaneous pathology, including nerve biverlose, immune cell changes, and vescular remodeling and epithelial stress. And this is very much aligned with how we think about this in my lab. We don't think go like plasma versus tissue, but we aim to connect systemic biomarkers with patient symptoms and local tissue biology. Going back to that question for a more direct answer, there are putically, I think, immune pathways are attracted. But we need to be careful because of these cancer patients. These are the cancer patients and cancer survivors. Their disease and treatments are deeply intertwined with the immune system. Immune responses can be damaging, but they can also participate in tissue repair, nerve repair, and of course, anti-tumor immunity and treatment response. So the goal should not be broad immune suppression, but rather identifying specific neuroimmune pathway, timing, and immune cell state, where targeting the immune response makes sense for patients. And then knowing which patient subgroup that we can actually apply those to without compromising cancer control or recovery. So overall, in order to get to the stage of Bioball Neuroimmune Biomarkers in CIPN, I think the next step is not simply measuring inflammation in patients, but it is understanding which immune state belongs to which patient and which time point, and whether that immune state is driving injury, repair, or more complex response to cancer treatment and nerve damage. Thank you so much. What experimental models do you think are critical for further understanding in this research area? And I suppose linking between this preclinical and clinical work, as you've mentioned. Yeah, that's a great question. I think more than models will continue to be essential for understanding this neuroimmacanisms, especially because they allow us to study tissue-specific immune response, and genetic tools are available, and we can measure behavior in ways that are difficult to apply in humans. Mouse and rat models have already told us a great deal about this field in relation to macrophages, cytokines, sensory neuron injury, and pain behavior. I also like to add that the non-memelium model, such as zirrophician, yourself, can also contribute. There are simpler systems, but aspects of neuronal injury and stress response and innate immunology, and chemotherapy toxicity are conserved as work from our lab and others have shown. These models can be powerful for rapid discovery and genetic screening, especially when they are paired with mammalian and human systems. But beyond the choice of model, I think one major need is better self-type resolution. NCIPN studies describe broad myeloid cell or macrophage involvement, but that is almost like talking about neurons as one category. We know neurons include many subtypes with different functions, and same is true for macrophages and other immune cells. We need to understand which new cell subsets are involved in different steps of CIPN, from initiation, progression, and generation pain and repair, and all the way to the transition of chronic symptoms for some patients. Other fields such as peripheral nerve injury and spinal cord injury have already developed more detailed ways of thinking about immune cell heterogeneity. So I think CIPN studies can benefit from adopting that level of rigor, especially if we want to identify more specific targets that doesn't interfere with the cancer treatment. In parallel, the field is moving towards patient-linked models. IPSC drive sensory neurons are being used more often, and there is a lot to learn from patient plasma, peripheral blood, one on nuclear cells, PBMCs, skin biopsy, and potentially patient-derived systems that can include both sensory neurons in immune cells. These approaches can help us model the patient-specific environment that determines why some individuals develop severe CIPN and others do not. I think this combination is very important to how we think about the problem in our own work. So using experimental systems, patient access for tissues, clinical information altogether. These models are complementary, but they're not mutually exclusive. M.O. models, cell culture systems, patient-derived models, and clinical data sets, I think, are each answering different questions. Across all of these systems, one major challenge that I see is that the model design really matters. Chimotherapy resumin, dose and rot, behavior SA, tissue, and time point can always shape what we see. That is especially important for immune response, because inflammatory readouts are often highly context and time-dependent. Some immune changes may be transient and occur early after chemotherapy exposure, so if we only look at one late time point, and we may miss the most important window and the reverse can be author true. And this is the point that is lacking in many studies in the field in general to compensate for that longitudinal animal and cell culture studies with carefully defined exposure conditions, tissues, and time points will be critical. And I think the same logic applies clinically. I would include longitudinal clinical data set as part of model building process. We need to understand not only what happens during chemotherapy or immediately after treatment, but also what was happening before the treatment and how symptoms evolve over time. So all together, I think the most important direction is back translation, especially for neuroimmune studies. I noticed this easier said than done, and even in our lab, we do not always aim to fully recreate the complexity of the patient environment. But rather, the goal is to identify which aspects of the environment are most relevant to the question that we're asking. Immune responses are strongly shaped by patient backgrounds such as age, comorbidity, prime inflammation, and treatment history. And if we ignore that context, our model may capture important mechanisms, but not necessarily the ones that explain why CIPM becomes severe or chronic in real patients. So I think we should use clinical observation whenever possible to build better models, not only asking whether pre-clinical findings can translate into patients. Thank you so much. You really gave us a broad perspective. To conclude our conversation, I would like to ask you what do you think is the most promising avenue in research in this field? Yeah, I think one of the most promising avenues is to connect deep patient phenotyping with mechanistic model systems in a much more intentional way. We have learned a great deal from pre-clinical models and we still have a lot to learn, but many groups in this field are now thinking carefully about how to connect those mechanistic insights back to what is actually happening in patients. And as you would agree, CIPM is not one uniform condition. It differs by chemotherapy class, cancer type, age, vulnerability, and baseline nerve cells, and importantly immune status. So the field needs larger, well phenotype patient cores where we can integrate things we discussed today, symptoms, functional outcomes, treatment exposure, plasma biomarker, skin biopsy, and a possible longitudinal clinical data. I think that will allow us to define biologically meaningful CIPM phenotypes rather than treating all patients as one group. At the same time, we need more modeled systems that are informed by those patient data. This is back translational point, I mentioned earlier. Instead of only asking whether animal or cell culture findings can translate into humans, we should also back translate from human observation into models. So if a subset of patients show a particular inflammatory neurocutaneous or external injury signature, we can then ask mechanistically whether the signature drives nerve dysfunction, pain, degeneration, or impaired repair that could compromise life quality for these patients in the long term. And this is also where my lab aims to contribute to the field. We aim to link careful clinical phenotyping, patient access for tissues like blood and skin, and experimental models. Our goal is not to just characterize CIPM, but to understand which mechanisms matter most for the patients we're trying to help. So I think neuroimmune pathways in this way are especially promising because they may provide both shared and distinct mechanisms across different cancer therapies. Different chemotherapy agents may initiate injuries through different upstream mechanisms because they affect different cellular targets. But some of those effects may converge on to targetable immune, inflammatory, or tissue remodeling pathways. Several groups are approaching this from different angles and bringing these perspectives together will be, I think it will be very important. And one unique opportunity in CIPM compared to other types of nerve injury is that it is something in some ways predictable. We know when patients are in neurotoxic therapy and that creates the possibility of identifying early immune or tissue responses that predict later in your office and potentially intervening before chronic symptoms become established. And many of us hope this will be one of the next meaningful advances we can make for patients. But as you may understand that prevention may not be the only opportunity, and indeed in cancer patients, prevention can be challenging because we have to avoid interfering with effective cancer treatment. So we also need to understand the transition from early chemotherapy induced injury to long-term inflammation, neuroinflammation, tissue remodeling, and chronic symptoms. The immune response during active chemotherapy may be very different from immune response years later in chronic CIPM. So those differences matter if we want to identify the right target and the right therapeutic window. So considering all this, ultimately I think the field is moving toward mechanism informed CIPM care, which is identifying which biological pathways active in which patients and which stage of disease and after which treatment exposure. So if we can do that as a field, I think we can move beyond treating CIPM as a one broad toxicity and began developing more precise mechanism informed strategies for prevention, monitoring, and intervention. Thank you so much Dr. Shinp for sharing your insights and find relevant papers in the show notes and visit www.pnssociety.com for more information about the peripheral nerve society. We'd also like to highlight the traumatic and toxic neuropathy consortium, which is a special interest group of the peripheral nerve society. The consortium encompasses pre-clinical and clinical experts from across the globe working together to increase knowledge and fund solutions for toxic neuropathy such as CIPM, as well as traumatic nerve damage. Please visit the PNS website for more information on how you can join the consortium. Thank you for listening. See you next month. The primary purpose of the peripheral nerve podcast is to meet the educational needs of its listeners and address practice gaps by providing practice oriented and scientifically-based education that will maintain an advanced competence and performance in the peripheral nerve field. A diversity of opinions exists in the medical field and the views of the podcast faculty do not represent those of the peripheral nerve society or constitute an endorsement by the peripheral nerve society.

Podcast Summary

Key Points:

  1. Neuroinflammation, particularly via innate immune pathways such as TLR-4, macrophages, and cytokines like TNF-α, IL-6, and IL-1β, plays a key role in chemotherapy-induced peripheral neuropathy (CIPN), though much evidence comes from preclinical models.
  2. Macrophages and microglia are central to neuroimmune crosstalk in CIPN, with macrophage heterogeneity and dynamic states varying by tissue location, timing, and disease stage—highlighting the need for precise characterization.
  3. The skin environment is actively involved in CIPN through neurocutaneous interactions, where cancer cells, immune cells, and epithelial stress can alter sensory neuron function and trigger inflammatory feedback loops.
  4. While inflammatory biomarkers show promise, their clinical utility is limited by patient heterogeneity, and more patient-centered, phenotype-driven biomarker approaches are needed to link immune states to symptoms.
  5. Tissue-based biomarkers, especially from skin biopsies, offer better insight into local neuroimmune changes than blood-based markers and can bridge preclinical findings with clinical reality.
  6. Experimental models—including mice, zebrafish, and patient-derived systems—should be used in concert with clinical data to improve model relevance and identify patient-specific mechanisms.
  7. A major research shift is toward patient phenotyping integrated with mechanistic models to define biologically distinct CIPN subtypes and tailor prevention and treatment strategies.
  8. The field is moving toward mechanism-informed, stage-specific care by identifying which neuroimmune pathways drive early injury versus chronic symptoms, enabling timely and targeted interventions.

Summary:

Chemotherapy-induced peripheral neuropathy (CIPN) is increasingly understood as a neuroimmune disorder rather than purely a direct neurotoxic effect. Preclinical studies highlight the role of innate immune activation—particularly through macrophages and cytokines—driven by sensory neuron injury and resulting in bidirectional neuroimmune crosstalk. However, translating these findings to patients remains challenging due to variability in cancer types, treatment regimens, and baseline immune status.

The skin, once viewed merely as a site of nerve fiber loss, is now recognized as a dynamic neurocutaneous environment where cancer cells, immune cells, and epithelial stress contribute to inflammation and sensory dysfunction. , skin biopsies) offers a more meaningful pathway for diagnosis and monitoring. Research is shifting toward integrated models that combine preclinical data with longitudinal clinical observations to identify distinct CIPN subtypes.

Key advances will come from understanding how immune responses evolve over time—from acute injury to chronic symptoms—and developing targeted, stage-specific therapies that do not compromise cancer treatment efficacy. Ultimately, the field aims toward mechanism-informed, personalized approaches to CIPN care, enabling early prediction, prevention, and effective intervention based on individual patient biology.

FAQs

Neuroinflammation is a major driver of CIPN, primarily through innate immune signaling in and around sensory nerves. Chemotherapy injures sensory neurons, triggering the release of damage signals like ATP, which activate macrophages, satellite glial cells, and microglia. These activated immune cells release cytokines (e.g., TNF-α, IL-6, IL-1β) that amplify neuronal sensitization and sustain nerve dysfunction through bi-directional neuroimmune crosstalk.

Macrophages are the most studied peripheral immune cells in CIPN, particularly in root ganglia and skin, where they show dynamic activation states. Microglia play a role in central sensitization and early pain signaling. Both cell types are heterogeneous and their contributions depend on chemotherapy type, timing, sex, and disease stage. Their roles shift from early injury to chronic phases, indicating a complex, time-dependent involvement.

The skin is an active neurocutaneous environment where sensory nerves interact with immune cells, fibroblasts, and epithelial cells. Chemotherapy may alter skin cells (e.g., carcinoma cells) to activate sensory signaling via ATP or mechanosensitive pathways. Nerve degeneration itself may trigger tissue inflammation through stress and repair responses, and local immune cell activation (e.g., mast cells, macrophages) can further drive neuroinflammation and sensory dysfunction.

Yes, neuroimmune pathways show potential as biomarkers and therapeutic targets, but not universally. Circulating cytokines alone are insufficient due to patient heterogeneity. More promising are patient-specific biomarker profiles linked to symptoms and tissue changes. Targeting specific immune states—rather than broad suppression—is safer and more effective, especially in balancing cancer treatment with nerve protection.

Mouse and rat models are essential for studying tissue-specific immune responses and pain behaviors. Non-mammalian models (e.g., zebrafish) offer rapid genetic screening. However, better models include patient-derived systems (e.g., iPSCs), skin biopsies, and longitudinal studies that account for timing, dose, and immune context. These models help bridge preclinical findings to patient-specific outcomes.

Deep patient phenotyping—integrating symptoms, treatment exposure, plasma biomarkers, and skin biopsy data—can identify distinct CIPN subtypes. This allows for mechanism-informed care, where therapies are tailored to individual immune and tissue profiles. It also enables early prediction of severe symptoms and supports targeted prevention or intervention before chronicity develops.

Chat with AI

Loading...

Pro features

Go deeper with this episode

Unlock creator-grade tools that turn any transcript into show notes and subtitle files.